Frank Harder

Nessuna posizione attualmente

Health Technology

Consumer Services

Commercial Services

Profilo

Frank Harder formerly worked at Bioporto A, as Chief Financial Officer & IR Contact from 2007 to 2014, Zymenex A, as Chief Financial Officer, and PhaseOneTrials A, as Chief Financial Officer.
Mr. Harder received his graduate degree from the University of Copenhagen.

Precedenti posizioni note di Frank Harder

Società	Posizione	Fine
BIOPORTO A/S	Direttore Finanziario/CFO	01/01/2014
Zymenex A/S Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark.	Direttore Finanziario/CFO	-
PhaseOneTrials A/S PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease.	Direttore Finanziario/CFO	-

Vedi nel dettaglio l'esperienza di Frank Harder

Formazione di Frank Harder

University of Copenhagen

Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Frank Harder

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
BIOPORTO A/S	Health Technology

Aziende private	2
Zymenex A/S Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark.	Health Technology
PhaseOneTrials A/S PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease.	Commercial Services